Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.70 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.70 |
| ▸ | MEN1 | O00255 | 2/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.65 |
| ▸ | POLB | P06746 | 2/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.65 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.60 |
| ▸ | CACNB4 | O00305 | 1/20 | 0.59 |
| ▸ | CACNA1A | O00555 | 1/20 | 0.59 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.59 |
| ▸ | CACNG3 | O60359 | 1/20 | 0.59 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.59 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.59 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL922442 | 0.98 | ALDH1A1 (0.68) | ALDH1A1KDM4ETDP1MEN1KMT2A | |
| SCHEMBL3568406 | 0.98 | ALDH1A1 (0.68) | ALDH1A1KDM4ETDP1MEN1KMT2A | |
| SCHEMBL15800712 | 0.93 | ALDH1A1 (0.78) | ALDH1A1KDM4ETDP1MEN1KMT2A | |
| SCHEMBL5578769 | 0.88 | ALDH1A1 (0.67) | ALDH1A1KDM4ETDP1MEN1KMT2A | |
| SCHEMBL374227 | 0.86 | ALDH1A1 (0.73) | ALDH1A1KDM4ETDP1MEN1KMT2A | |
| SCHEMBL29531890 | 0.86 | ALDH1A1 (0.65) | ALDH1A1KDM4ETDP1MEN1KMT2A | |
| SCHEMBL28677028 | 0.86 | ALDH1A1 (0.65) | ALDH1A1KDM4ETDP1MEN1KMT2A | |
| SCHEMBL357155 | 0.86 | ALDH1A1 (0.67) | ALDH1A1KDM4ETDP1MEN1KMT2A | |
| SCHEMBL2716970 | 0.86 | ALDH1A1 (0.73) | ALDH1A1KDM4ETDP1MEN1KMT2A | |
| SCHEMBL2657985 | 0.86 | ALDH1A1 (0.65) | ALDH1A1KDM4ETDP1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12358869-B2 | Diarylureas as CB1 allosteric modulators | RESEARCH TRIANGLE INSTITUTE | 2025-07-15 | — | — | US | disclosed |
| US-20210332007-A1 | DIARYLUREAS AS CB1 ALLOSTERIC MODULATORS | RESEARCH TRIANGLE INSTITUTE | 2021-10-28 | — | — | US | disclosed |
| US-11084781-B2 | Diarylureas as CB1 allosteric modulators | RESEARCH TRIANGLE INSTITUTE (US) | 2021-08-10 | — | — | US | disclosed |
| EP-3621951-A1 | DIARYLUREAS AS CB1 ALLOSTERIC MODULATORS | Research Triangle Institute (US) | 2020-03-18 | — | — | EP | disclosed |
| US-20200062699-A1 | DIARYLUREAS AS CB1 ALLOSTERIC MODULATORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-02-27 | — | — | US | disclosed |
| WO-2018209030-A1 | DIARYLUREAS AS CB1 ALLOSTERIC MODULATORS | RTI INTERNATIONAL (US) | 2018-11-15 | — | — | WO | disclosed |
| EP-2315763-B1 | BENZIMIDAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC (US) | 2016-06-01 | — | — | EP | disclosed |
| EP-2315763-B1 | BENZIMIDAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC (US) | 2016-06-01 | — | — | EP | disclosed |
| EP-2273992-B1 | QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC (US) | 2016-05-25 | — | — | EP | disclosed |
| EP-2273992-B1 | QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC (US) | 2016-05-25 | — | — | EP | disclosed |
| EP-1562898-A1 | INDOLE DERIVATIVES AS SOMATOSTATIN AGONISTS OR ANTAGONISTS | Takeda Pharmaceutical Company Limited (JP) | 2005-08-17 | — | — | EP | disclosed |
| EP-1450791-A1 | HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS | Kinetek Pharmaceuticals, Inc. (CA) | 2004-09-01 | — | — | EP | disclosed |
| WO-2004046107-A1 | INDOLE DERIVATIVES AS SOMATOSTATIN AGONISTS OR ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-06-03 | — | — | WO | disclosed |
| US-6710044-B2 | Technical field | NEUROSEARCH A/S (DK) | 2004-03-23 | — | — | US | disclosed |
| US-20030166638-A1 | Benzimidazole's used as aminobutyric acid receptor modulators, for prophylaxis of nervous system disorders such as anxiety, sleep disorders, epilepsia or convulsions | NEUROSEARCH A/S | 2003-09-04 | — | — | US | disclosed |
| WO-2003045379-A1 | HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS | KINETEK PHARMACEUTICALS, INC. (CA) | 2003-06-05 | — | — | WO | disclosed |
| US-6503925-B1 | Treating anxiety, anesthesia, and epilepsy | NEUROSEARCH A/S (DK) | 2003-01-07 | — | — | US | disclosed |
| US-6218547-B1 | 1-phenyl-benzimidazole compounds and their use as GABA-a receptor modulators | NEUROSEARCH A/S (DK) | 2001-04-17 | — | — | US | disclosed |
| EP-0934281-A1 | 1-PHENYL-BENZIMIDAZOLE COMPOUNDS AND THEIR USE AS BAGA- A? RECEPTOR MODULATORS | NEUROSEARCH A/S (DK) | 1999-08-11 | — | — | EP | disclosed |
| WO-1998017651-A1 | 1-PHENYL-BENZIMIDAZOLE COMPOUNDS AND THEIR USE AS BAGA-A RECEPTOR MODULATORS | NEUROSEARCH A/S (DK) | 1998-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166638-A1 | Benzimidazole's used as aminobutyric acid receptor modulators, for prophylaxis of nervous system disorders such as anxiety, sleep disorders, epilepsia or convulsions | GABRA1, GABRA2, GABRA4 | ALDH1A1 192/4885KDM4E 1061/4885TDP1 1904/4885 |
| US-12358869-B2 | Diarylureas as CB1 allosteric modulators | CNR1, CNR2, GPR18 | ALDH1A1 2918/4885KDM4E 1019/4885TDP1 4211/4885 |
| US-11084781-B2 | Diarylureas as CB1 allosteric modulators | CNR1, CNR2, GPR18 | ALDH1A1 2918/4885KDM4E 1019/4885TDP1 4211/4885 |
| US-20200062699-A1 | DIARYLUREAS AS CB1 ALLOSTERIC MODULATORS | CNR1, CNR2, GPR18 | ALDH1A1 2918/4885KDM4E 1019/4885TDP1 4211/4885 |
| US-20210332007-A1 | DIARYLUREAS AS CB1 ALLOSTERIC MODULATORS | CNR1, CNR2, GPR18 | ALDH1A1 2918/4885KDM4E 1019/4885TDP1 4211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.